A UK feasibility and validation study of the VE1 monoclonal antibody immunohistochemistry stain for BRAF-V600E mutations in metastatic melanoma

BACKGROUND: Determining the BRAF mutation status of patients with advanced metastatic melanoma is essential in order to assess patients' eligibility for targeted BRAF inhibitor therapy. The aim of this study was to validate the utility of immunohistochemistry (IHC) to rapidly obtain the BRAF st...

Descripción completa

Detalles Bibliográficos
Autores principales: Lo, Michelle Chin I, Paterson, Anna, Maraka, Jane, Clark, Richard, Goodwill, Joseph, Nobes, Jenny, Garioch, Jennifer, Moncrieff, Marc, Rytina, Ed, Igali, Laszlo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Molecular Diagnostics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4947692/
https://www.ncbi.nlm.nih.gov/pubmed/27336602
http://dx.doi.org/10.1038/bjc.2016.106

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4947692/
https://www.ncbi.nlm.nih.gov/pubmed/27336602
http://dx.doi.org/10.1038/bjc.2016.106

Ejemplares similares